Toxicologic Bradycardia: An evidence approach to beta blocker and calcium channel blocker toxicity

After participation in this session, learners will be able to:

• List causes of toxicologic bradycardia
• Formulate a stepwise approach to  beta blocker (BB) and calcium channel blocker (CCB) toxicity
• Describe the evidence and application of high dose insulin therapy

Dr. Riley Hartmann is the Associate Medical Director of the Poison and Drug Information Service and an emergency physician in Saskatoon, Saskatchewan. Additionally, he is the provincial lead for toxicology for Saskatchewan. Riley completed his Clinical Pharmacology and Toxicology Fellowship at the University of Calgary and continues to provide consultation services for both PADIS and the Clinical Pharmacology Consult service at the University of Calgary.